{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:55:32Z","timestamp":1790898932674,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Province Gastrointestinal, Respiratory, Genitourinary Malignant Tumor Radiotherapy Radiation and Treatment Clinical Medical Research Center","award":["2021Y2014"],"award-info":[{"award-number":["2021Y2014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16433-0","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:32:57Z","timestamp":1783038777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging data-driven risk-adapted surveillance strategies after disease progression in locally advanced rectal cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Jianjian","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingdong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"16433_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115\u201332. https:\/\/doi.org\/10.3322\/caac.21338.","journal-title":"CA Cancer J Clin"},{"key":"16433_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/cac2.12639","volume":"45","author":"F Wang","year":"2025","unstructured":"Wang F, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update. Cancer Commun (Lond). 2025;45:332\u201379. https:\/\/doi.org\/10.1002\/cac2.12639.","journal-title":"Cancer Commun (Lond)"},{"key":"16433_CR3","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.6004\/jnccn.2022.7056","volume":"20","author":"D Lang","year":"2022","unstructured":"Lang D, Ciombor KK. Diagnosis and management of rectal cancer in patients younger than 50 years: rising global incidence and unique challenges. J Natl Compr Canc Netw. 2022;20:1169\u201375. https:\/\/doi.org\/10.6004\/jnccn.2022.7056.","journal-title":"J Natl Compr Canc Netw"},{"key":"16433_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrclinonc.2011.118","volume":"8","author":"M Aklilu","year":"2011","unstructured":"Aklilu M, Eng C. The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol. 2011;8:649\u201359. https:\/\/doi.org\/10.1038\/nrclinonc.2011.118.","journal-title":"Nat Rev Clin Oncol"},{"key":"16433_CR5","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41575-020-0275-y","volume":"17","author":"DS Keller","year":"2020","unstructured":"Keller DS, Berho M, Perez RO, Wexner SD, Chand M. The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol. 2020;17:414\u201329. https:\/\/doi.org\/10.1038\/s41575-020-0275-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"16433_CR6","doi-asserted-by":"publisher","first-page":"1149122","DOI":"10.3389\/fimmu.2023.1149122","volume":"14","author":"W Xiao","year":"2023","unstructured":"Xiao W, et al. Total neoadjuvant treatment and PD-1\/PD-L1 checkpoint inhibitor in locally advanced rectal cancer. Front Immunol. 2023;14:1149122. https:\/\/doi.org\/10.3389\/fimmu.2023.1149122.","journal-title":"Front Immunol"},{"key":"16433_CR7","doi-asserted-by":"publisher","first-page":"1631620","DOI":"10.3389\/fimmu.2025.1631620","volume":"16","author":"Y He","year":"2025","unstructured":"He Y, Gu W, Shao Y. Research progress on immunotherapy combined with neoadjuvant concurrent chemoradiotherapy in pMMR\/MSS locally advanced rectal cancer. Front Immunol. 2025;16:1631620. https:\/\/doi.org\/10.3389\/fimmu.2025.1631620.","journal-title":"Front Immunol"},{"key":"16433_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12094-015-1462-0","volume":"18","author":"J Arredondo","year":"2016","unstructured":"Arredondo J, et al. Patterns and management of distant failure in locally advanced rectal cancer: a cohort study. Clin Transl Oncol. 2016;18:909\u201314. https:\/\/doi.org\/10.1007\/s12094-015-1462-0.","journal-title":"Clin Transl Oncol"},{"key":"16433_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/SLA.0000000000003002","volume":"269","author":"J Fleshman","year":"2019","unstructured":"Fleshman J, et al. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. Ann Surg. 2019;269:589\u201395. https:\/\/doi.org\/10.1097\/SLA.0000000000003002.","journal-title":"Ann Surg"},{"key":"16433_CR10","doi-asserted-by":"publisher","first-page":"e2340256","DOI":"10.1001\/jamanetworkopen.2023.40256","volume":"6","author":"M Diefenhardt","year":"2023","unstructured":"Diefenhardt M, et al. Overall Survival After Treatment Failure Among Patients With Rectal Cancer. JAMA Netw Open. 2023;6:e2340256. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.40256.","journal-title":"JAMA Netw Open"},{"key":"16433_CR11","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926\u201333. https:\/\/doi.org\/10.1200\/JCO.2011.40.1836.","journal-title":"J Clin Oncol"},{"key":"16433_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.annonc.2025.01.006","volume":"36","author":"H Williams","year":"2025","unstructured":"Williams H, et al. Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO\/ARO\/AIO-12 and OPRA randomized phase II trials. Ann Oncol. 2025;36:543\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.006.","journal-title":"Ann Oncol"},{"key":"16433_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10637-018-0589-6","volume":"36","author":"A Kasuga","year":"2018","unstructured":"Kasuga A, et al. Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis. Invest New Drugs. 2018;36:939\u201348. https:\/\/doi.org\/10.1007\/s10637-018-0589-6.","journal-title":"Invest New Drugs"},{"key":"16433_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/1759-7714.12463","volume":"8","author":"H Imai","year":"2017","unstructured":"Imai H, Kaira K, Minato K. Clinical significance of post-progression survival in lung cancer. Thorac Cancer. 2017;8:379\u201386. https:\/\/doi.org\/10.1111\/1759-7714.12463.","journal-title":"Thorac Cancer"},{"key":"16433_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/1759-7714.13886","volume":"12","author":"H Imai","year":"2021","unstructured":"Imai H, et al. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer. Thorac Cancer. 2021;12:1171\u20139. https:\/\/doi.org\/10.1111\/1759-7714.13886.","journal-title":"Thorac Cancer"},{"key":"16433_CR16","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1111\/1759-7714.14621","volume":"13","author":"K Masubuchi","year":"2022","unstructured":"Masubuchi K, et al. Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival. Thorac Cancer. 2022;13:2776\u201385. https:\/\/doi.org\/10.1111\/1759-7714.14621.","journal-title":"Thorac Cancer"},{"key":"16433_CR17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/hepr.13986","volume":"54","author":"K Tajiri","year":"2024","unstructured":"Tajiri K, Muraishi N, Murayama A, Hayashi Y, Yasuda I. Impact of post-progression survival in second-line treatment with molecular target agents for unresectable hepatocellular carcinoma. Hepatol Res. 2024;54:403\u20138. https:\/\/doi.org\/10.1111\/hepr.13986.","journal-title":"Hepatol Res"},{"key":"16433_CR18","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.ejca.2014.03.012","volume":"50","author":"S Negrier","year":"2014","unstructured":"Negrier S, et al. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer. 2014;50:1766\u201371. https:\/\/doi.org\/10.1016\/j.ejca.2014.03.012.","journal-title":"Eur J Cancer"},{"key":"16433_CR19","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.3802\/jgo.2020.31.e94","volume":"31","author":"E Kondo","year":"2020","unstructured":"Kondo E, et al. The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017\/GCIG. J Gynecol Oncol. 2020;31:e94. https:\/\/doi.org\/10.3802\/jgo.2020.31.e94.","journal-title":"J Gynecol Oncol"},{"key":"16433_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/13696998.2016.1219358","volume":"20","author":"C Parker","year":"2017","unstructured":"Parker C, et al. Brentuximab vedotin in relapsed\/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. J Med Econ. 2017;20:8\u201318. https:\/\/doi.org\/10.1080\/13696998.2016.1219358.","journal-title":"J Med Econ"},{"key":"16433_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10928-022-09816-w","volume":"49","author":"M Nagase","year":"2022","unstructured":"Nagase M, Doshi S, Dutta S, Lin CW. Estimation of time to progression and post progression survival using joint modeling of summary level OS and PFS data with an ordinary differential equation model. J Pharmacokinet Pharmacodyn. 2022;49:455\u201369. https:\/\/doi.org\/10.1007\/s10928-022-09816-w.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"16433_CR22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.7150\/jca.17664","volume":"9","author":"M Shimokawa","year":"2018","unstructured":"Shimokawa M, et al. Overall survival and post-progression survival are potent endpoint in phase III trials of second\/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer. J Cancer. 2018;9:872\u20139. https:\/\/doi.org\/10.7150\/jca.17664.","journal-title":"J Cancer"},{"key":"16433_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/liv.15825","volume":"44","author":"S Kobayashi","year":"2024","unstructured":"Kobayashi S, et al. Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma. Liver Int. 2024;44:1343\u201350. https:\/\/doi.org\/10.1111\/liv.15825.","journal-title":"Liver Int"},{"key":"16433_CR24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11454-y","author":"LQ Yao","year":"2022","unstructured":"Yao LQ, et al. Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-11454-y.","journal-title":"Ann Surg Oncol"},{"key":"16433_CR25","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/ejcts\/ezab442","volume":"61","author":"T Isaka","year":"2022","unstructured":"Isaka T, et al. Impact of the initial site of recurrence on prognosis after curative surgery for primary lung cancer. Eur J Cardiothorac Surg. 2022;61:778\u201386. https:\/\/doi.org\/10.1093\/ejcts\/ezab442.","journal-title":"Eur J Cardiothorac Surg"},{"key":"16433_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jamaoncol.2024.5672","volume":"11","author":"J Saal","year":"2025","unstructured":"Saal J, et al. Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy. JAMA Oncol. 2025;11:154\u201361. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5672.","journal-title":"JAMA Oncol"},{"key":"16433_CR27","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00262-020-02613-9","volume":"69","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, et al. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of >\/= 50. Cancer Immunol Immunother. 2020;69:2209\u201321. https:\/\/doi.org\/10.1007\/s00262-020-02613-9.","journal-title":"Cancer Immunol Immunother"},{"key":"16433_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2021.02.005","volume":"148","author":"A Cortellini","year":"2021","unstructured":"Cortellini A, et al. Post-progression outcomes of NSCLC patients with PD-L1 expression >\/= 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. Eur J Cancer. 2021;148:24\u201335. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.005.","journal-title":"Eur J Cancer"},{"key":"16433_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jtha.2024.10.002","volume":"23","author":"S Hui","year":"2025","unstructured":"Hui S, et al. Management and outcomes in patients with tumor thrombus: a retrospective cohort study. J Thromb Haemost. 2025;23:201\u20139. https:\/\/doi.org\/10.1016\/j.jtha.2024.10.002.","journal-title":"J Thromb Haemost"},{"key":"16433_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.07.043","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. ITGA5-expressing tumor cells interact with Schwann cells to drive nerve growth factor-mediated immunosuppression of NK cells. Mol Ther. 2025. https:\/\/doi.org\/10.1016\/j.ymthe.2025.07.043.","journal-title":"Mol Ther"},{"key":"16433_CR31","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1007\/s00330-025-11491-7","volume":"35","author":"Q Li","year":"2025","unstructured":"Li Q, et al. CT-based scores for extramural vascular invasion and occult peritoneal metastasis correlate with gastric cancer survival. Eur Radiol. 2025;35:5733\u201347. https:\/\/doi.org\/10.1007\/s00330-025-11491-7.","journal-title":"Eur Radiol"},{"key":"16433_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/PAS.0000000000002048","volume":"47","author":"Z Lin","year":"2023","unstructured":"Lin Z, et al. Identification and Prognostic Effect of Extramural Venous Invasion in Locally Advanced Esophageal Squamous Cell Carcinoma. Am J Surg Pathol. 2023;47:766\u201373. https:\/\/doi.org\/10.1097\/PAS.0000000000002048.","journal-title":"Am J Surg Pathol"},{"key":"16433_CR33","doi-asserted-by":"publisher","unstructured":"Bhutiani N et al. Does Extramural Vascular Invasion Predict Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer? Clin Colorectal Cancer 2025;24:272\u2013279 e272. https:\/\/doi.org\/10.1016\/j.clcc.2025.02.002.","DOI":"10.1016\/j.clcc.2025.02.002"},{"key":"16433_CR34","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.7150\/ijbs.111732","volume":"21","author":"Z Bian","year":"2025","unstructured":"Bian Z, et al. Modulating the Immunosuppressive Tumor Microenvironment and Inhibiting Growth in Mutp53-Driven CRPC via STAT3 Pathway Blockade. Int J Biol Sci. 2025;21:3081\u201398. https:\/\/doi.org\/10.7150\/ijbs.111732.","journal-title":"Int J Biol Sci"},{"key":"16433_CR35","doi-asserted-by":"publisher","first-page":"e70570","DOI":"10.1111\/liv.70570","volume":"46","author":"T Matono","year":"2026","unstructured":"Matono T, et al. Lymphocyte-Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab. Liver Int. 2026;46:e70570. https:\/\/doi.org\/10.1111\/liv.70570.","journal-title":"Liver Int"},{"key":"16433_CR36","doi-asserted-by":"publisher","first-page":"115489","DOI":"10.1016\/j.ejca.2025.115489","volume":"223","author":"C Dauccia","year":"2025","unstructured":"Dauccia C, et al. Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial. Eur J Cancer. 2025;223:115489. https:\/\/doi.org\/10.1016\/j.ejca.2025.115489.","journal-title":"Eur J Cancer"},{"key":"16433_CR37","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12885-022-09589-y","volume":"22","author":"M Kohls","year":"2022","unstructured":"Kohls M, et al. Impact of cumulative body mass index and cardiometabolic diseases on survival among patients with colorectal and breast cancer: a multi-centre cohort study. BMC Cancer. 2022;22:546. https:\/\/doi.org\/10.1186\/s12885-022-09589-y.","journal-title":"BMC Cancer"},{"key":"16433_CR38","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.annonc.2025.09.004","volume":"36","author":"C Lepage","year":"2025","unstructured":"Lepage C, et al. Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial. Ann Oncol. 2025;36:1468\u201379. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.004.","journal-title":"Ann Oncol"},{"key":"16433_CR39","doi-asserted-by":"publisher","first-page":"CD002200","DOI":"10.1002\/14651858.CD002200.pub4","volume":"9","author":"M Jeffery","year":"2019","unstructured":"Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2019;9:CD002200. https:\/\/doi.org\/10.1002\/14651858.CD002200.pub4.","journal-title":"Cochrane Database Syst Rev"},{"key":"16433_CR40","doi-asserted-by":"publisher","first-page":"366","DOI":"10.6004\/jnccn.2024.0041","volume":"22","author":"AB Benson","year":"2024","unstructured":"Benson AB, et al. NCCN Guidelines(R) Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:366\u201375. https:\/\/doi.org\/10.6004\/jnccn.2024.0041.","journal-title":"J Natl Compr Canc Netw"},{"key":"16433_CR41","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.annonc.2025.05.528","volume":"36","author":"RD Hofheinz","year":"2025","unstructured":"Hofheinz RD, et al. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:1007\u201324. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.528.","journal-title":"Ann Oncol"},{"key":"16433_CR42","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41587-025-02731-8","volume":"44","author":"CW Ju","year":"2026","unstructured":"Ju CW, et al. Modifications of microbiome-derived cell-free RNA in plasma discriminates colorectal cancer samples. Nat Biotechnol. 2026;44:752\u20138. https:\/\/doi.org\/10.1038\/s41587-025-02731-8.","journal-title":"Nat Biotechnol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16433-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16433-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16433-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:23:10Z","timestamp":1790896990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16433-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16433"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16433-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the principles of the Helsinki Declaration and approved by the Ethics Committee of Fujian Provincial Tumor Hospital. As this study is a retrospective study, there is no need to seek further informed consent from the patients related to this study.\u201d","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1163"}}